 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| Lucentis (ranibizumab) / Roche, Novartis, Rimmyrah (ranibizumab biosimilar) / Biocad, Qilu Pharma
P3 data, Journal: Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-related Macular Degeneration: A Phase 3 Randomized Trial. (Pubmed Central) - Apr 5, 2025
QL1205 was biosimilar to reference ranibizumab regarding clinical efficacy, ocular and systemic safety, as well as immunogenicity and pharmacokinetics profiles in the treatment of patients with nAMD.
- |||||||||| Rimmyrah (ranibizumab biosimilar) / Biocad, Qilu Pharma
New P3 trial: A Multicenter Study to Compare Efficacy and Safety of QL1205 Versus Lucentis (EUDRACT) - Apr 30, 2019
P3, N=656, Ongoing, Sponsor: Qilu Pharmaceutical Co., Ltd.
- || Rimmyrah (ranibizumab biosimilar) / Biocad, Qilu Pharma
Trial completion, Trial completion date, Trial primary completion date: Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis (clinicaltrials.gov) - Apr 11, 2019
P1, N=48, Completed, Sponsor: Qilu Pharmaceutical Co., Ltd.
QL1205 was biosimilar to reference ranibizumab regarding clinical efficacy, ocular and systemic safety, as well as immunogenicity and pharmacokinetics profiles in the treatment of patients with nAMD. Recruiting --> Completed | Trial completion date: Oct 2018 --> Apr 2019 | Trial primary completion date: Oct 2018 --> Apr 2019
- | Rimmyrah (ranibizumab biosimilar) / Biocad, Qilu Pharma
New P1 trial: Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis (clinicaltrials.gov) - Oct 17, 2017
P1, N=48, Recruiting, Sponsor: Qilu Pharmaceutical Co., Ltd.